Clinical pharmacokinetics of mexiletine

Clinical Pharmacokinetics

Volumn 37, Issue 5, 1999, Pages 361-384

  Labbé, Line ^a   Turgeon, Jacques ^a,b,c  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIARRHYTHMIC AGENT; ATROPINE; CIPROFLOXACIN; DRUG METABOLITE; METOCLOPRAMIDE; MEXILETINE; OPIATE; PHENYTOIN; PROPAFENONE; RIFAMPICIN;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0032755591     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937050-00002     Document Type: Review

References (148)

1. 1. Campbell NPS, Kelly JG, Shanks RG, et al. Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet 1973; II: 404-7
2. 2. Campbell RWF, Dolder MA, Prescott LF, et al. Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction. Lancet 1975; I: 1257-9
3. 3. Talbot RG, Nimmo J, Julian DG, et al. Treatment of ventricular arrhythmias with mexiletine (Kö 1173). Lancet 1973; II: 399-403
4. 4. Chew CYC, Collett J, Singh BN. Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias. Drugs 1979; 17: 161-81
5. 5. Akiyama M, Sugimoto T, Uraoka T, et al. Electrophysiological effects of mexiletine in man. Jpn Heart J 1982; 23: 237-9
6. 6. Sami M, Lishona R. Mexiletine: long-term efficacy and hemodynamic actions in patients with ventricular arrhythmia. Can J Cardiol 1985; 1: 251-8
7. 7. Stein J, Podrid P, Lown B. Effects of oral mexiletine on left and right ventricular function. Am J Cardiol 1984; 54: 575-8
8. 8. Sheldon RS, Duff HJ, Mitchell LB, et al. Effect of oral combination therapy with mexiletine and quinidine on left and right ventricular function. Am Heart J 1988; 115: 1030-6
9. 9. Duff HJ, Roden D, Primm RK, et al. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Circulation 1983; 67: 1124-8
10. 10. Leahey Jr EB, Heissenbuttel RH, Giardina EGV, et al. Combined mexiletine and propranolol treatment of refractory ventricular tachycardia. BMJ 1980; 281: 357-8
11. 11. Valenzuela C, Sanchez-Chapula J. Electrophysiologic interactions between mexiletine-quinidine and mexiletine-ropitoin in guinea pig papillary muscle. J Cardiovasc Pharmacol 1989; 14: 783-9
12. 12. Costard-Jaeckle A, Liem BL, Franz MR. Frequency-dependent effect of quinidine, mexiletine and their combination of postrepolarizalion refractoriness in vivo. J Cardiovasc Pharmacol 1989; 14: 810-7
13. 13. Duff HJ, Cannon NJ, Sheldon RS. Mexiletine-quinidine in isolated hearts: an interaction involving the sodium channel. Cardiovasc Res 1989; 23: 584-92
14. 14. Duff HJ, Kolodgie FD, Roden DM, et al. Electropharmacologic synergism with mexiletine and quinidine. J Cardiovasc Pharmacol 1986; 8: 840-6
15. 15. Duff HJ. Mexiletine-quinidine combination: enhanced antiarrhythmic and electrophysiologic activity in the dog. J Pharmacol Exp Ther 1989; 249: 617-22
16. 16. Roden DM, Iansmith DHS, Woosley RL. Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. J Pharmacol Exp Ther 1987; 243: 1218-24
17. 17. Duff HJ, Rahmberg M, Sheldon RS. Role of quinidine in the mexiletine-quinidine interaction: electrophysiologic correlates of enhanced antiarrhythmic efficacy. J Cardiovasc Pharmacol 1990; 16: 685-92
18. 18. Turgeon J, Fiset C, Giguère R, et al. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. J Pharmacol Exp Ther 1991; 259: 789-98
19. 19. Yeung-Lai-Wah JA, Murdock CJ, Boone J, et al. Propafenone-mexiletine combination for the treatment of sustained ventricular tachycardia. J Am Coll Cardiol 1992; 20: 547-51
20. 20. Valenzuela C, Delpón E, Tamargo J. Electrophysiologic interactions between mexiletine and propafenone in guinea pig papillary muscles. J Cardiovasc Pharmacol 1989; 14: 351-7
21. 21. Breithardt G, Seipel I, Abendroth RR. Comparison of the antiarrhythmic efficacy of disopyramide and mexiletine against stimulus-induced ventricular tachycardia. J Cardiovasc Pharmacol 1981; 3: 1026-37
22. 22. Lüderitz B, Mletzko R, Jung W, et al. Combination of antiarrhythmic drugs. J Cardiovasc Pharmacol 1991; 17 Suppl. 6: S48-52
23. 23. Wagner WL, Manz M, Luderitz B. Combination of sotalol with the class IB substances mexiletine or tocainide in complex ventricular extrasystole. Z Kardiol 1987; 76: 296-302
24. 24. Greenspan AM, Spielman SR, Webb CR, et al. Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease. Am J Cardiol 1985; 56: 277-84
25. 25. Tanabe T, Takahashi K, Yoshioka K, et al. Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease. Int J Cardiol 1991; 32: 303-12
26. 26. Toivonen L, Kadish A, Morady F. A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia. Circulation 1991; 84: 101-8
27. 27. Hoffmann A, Follath F, Burckhardt D. Safe treatment of resistant ventricular arrhythmias with combination of amiodarone and quinidine or mexiletine. Lancet 1983; I: 704-5
28. 28. Waleffe A, Mary-Rabine L, Legrand V, et al. Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia. Am Heart J 1980; 100: 788-93
29. 29. Campbell NPS, Kelly JG, Adgey AAJ, et al. The clinical pharmacology of mexiletine. Br J Clin Pharmacol 1978; 6: 103-8
30. 30. Peyrieux JC, Boissel JP, Leizorovicz A, et al. Relationship between plasma mexiletine levels at steady-state. Presence of ventricular arrhythmias and side effects. Fundam Clin Pharmacol 1987; I: 45-57
31. 31. Lévy-Prades R, Philip F, Danays T, et al. Pharmacocinétique de la mexiletine et de son métabolite hydroxyméthyle après administration intramusculaire et intraveineuse de mexilétine chez le sujet sain. Therapie 1987; 42: 3-7
32. 32. Bradbrook ID, Feldschreiber P, Morrison PJ, et al. Plasma mexiletine concentrations following combined oral and intramuscular administration. Eur J Clin Pharmacol 1981; 19: 301-4
33. 33. Prescott LF, Pottage A, Clements JA. Absorption, distribution and elimination of mexiletine. Postgrad Med J 1977; 53 Suppl. 1: 50-5
34. 34. Häselbarth V, Doevendans JE, Wolf M. Kinetics and bioavailability of mexiletine in healthy subjects. Clin Pharmacol Ther 1981; 29: 729-36
35. 35. Klein A, Sami M, Selinger K. Mexiletine kinetics in healthy subjects taking cimetidine. Clin Pharmacol Ther 1985; 37: 669-73
36. 36. Herzog P, Holtermüller KH, Kasper W, et al. Absorption of mexiletine after treatment with gastric antacids. Br J Clin Pharmacol 1982; 14: 746-7
37. 37. Holt DW, Chadwick DE, Campbell RWF. Absorption and antiarrhythmic efficacy of sustained-release mexiletine. Clin Ther 1983; 5: 268-78
38. 38. Pringle T, Fox J, McNeill JA, et al. Dose independent pharmacokinetics of mexiletine in healthy volunteers. Br J Clin Pharmacol 1986; 21: 319-21
39. 39. Campbell NPS, Kelly JG, Adgey AAJ, et al. Mexiletine in normal volunteers. Br J Clin Pharmacol 1978; 6: 372-3
40. 40. Broly F, Vandamme N, Libersa C, et al. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation. Br J Clin Pharmacol 1991; 32: 459-66
41. 41. Rohrig TP, Harty LE. Postmortem distribution of mexiletine in a fatal overdose. J Anal Toxicol 1994; 18: 354-5
42. 42. Turgeon J, Grech-Bélanger O, Gilbert M. Erythrocyte and serum distribution of mexiletine in man. Biopharm Drug Dispos 1987; 8: 571-6
43. 43. Lownes HE, Ives TJ. Mexiletine use in pregnancy and lactation. Am J Obstet Gynecol 1987; 157: 446-7
44. 44. Timmis AD, Jackson G, Holt DW. Mexiletine for control of ventricular dysrhythmias in pregnancy. Lancet 1980; II: 647-8
45. 45. Gregg AR, Tomich PG. Mexiletine use in pregnancy. J Perinatol 1988; 8: 33-5
46. 46. Lewis AM, Patel L, Johnston A, et al. Mexiletine in human blood and breast milk. Postgrad Med J 1981; 57: 546-7
47. 47. Kwok DW, Kerr CR, McErlane KM. Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. Xenobiotica 1995; 25: 1127-42
48. 48. Beckett AH, Chidomere EC. The identification and analysis of mexiletine and its metabolic products in man. J Pharm Pharmacol 1977; 29: 281-5
49. 49. Grech-Bélanger O, Gilbert M, Turgeon J, et al. Effect of cigarette smoking on mexiletine kinetics. Clin Pharmacol Ther 1985; 37: 638-43
50. 50. Turgeon J, Paré JRJ, Lalande M, et al. Isolation and structural characterization by spectroscopic methods of two glucuronide metabolites of mexiletine after N-oxidation and deamination. Drug Metab Dispos 1992; 20: 762-9
51. 51. Grech-Bélanger O, Turgeon J, Lalande M, et al. Metahydroxymexiletine, a new metabolite of mexiletine. Isolation, characterization, and species differences in its formation. Drug Metab Dispos 1991; 19: 458-61
52. 52. Grech-Bélanger O, Turgeon J, Lalande M. 2,6-Dimethylphenol: a new metabolite of mexiletine. Res Commun Chem Pathol Pharmacol 1987; 58: 53-62
53. 53. Grech-Bélanger O, Turgeon J, Gilbert M. Stereoselective disposition of mexiletine in man. Br J Clin Pharmacol 1986; 21: 481-7
54. 54. Kiddie MA, Kaye CM, Turner P, et al. The influence of urinary pH on the elimination of mexiletine. Br J Clin Pharmacol 1974; 1: 229-32
55. 55. Kaye CM, Kiddie MA, Turner P. Variable pharmacokinetics of mexiletine. Postgrad Med J 1977; 53 Suppl. 1: 56-8
56. 56. Mitchell BG, Clements JA, Pottage A, et al. Mexiletine disposition: individual variation in response to urine acidification and alkalinisation. Br J Clin Pharmacol 1983; 16: 281-4
57. 57. Johnston A, Burgess CD, Henry JA, et al. Mexiletine elimination: influence of urinary pH and volume. Br J Pharmacol 1981; 72: 135P
58. 58. Beckett AH, Chidomere EC. The distribution, metabolism and excretion of mexiletine in man. Postgrad Med J 1977; 53 Suppl. 1: 60-6
59. 59. Johnston A, Burgess CD, Warrington SJ, et al. The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers. Br J Clin Pharmacol 1979; 8: 349-52
60. 60. Pentikäinen PJ, Hietakorpi S, Halinen MO, et al. Cirrhosis of the liver markedly impairs the elimination of mexiletine. Eur J Clin Pharmacol 1986; 30: 83-8
61. 61. Lledó P, Abrams SML, Johnston A, et al. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. Eur J Clin Pharmacol 1993; 44: 63-7
62. 62. Clark RA, Julian DG, Nimmo J, et al. Clinical pharmacological studies of Kö 1173: a new antiarrhythmic agent. Proc Br Pharmacol Soc 1973; 47: 622P-3P
63. 63. Wing LMH, Meffin PJ, Grygiel JJ, et al. The effect of metoclopramide and atropine on the absorption of orally administered mexiletine. Br J Clin Pharmacol 1980; 9: 505-9
64. 64. Begg EJ, Chinwah PM, Webb C, et al. Enhanced metabolism of mexiletine after phenytoin administration. Br J Clin Pharmacol 1982; 14: 219-23
65. 65. Pentikäinen PJ, Koivula IH, Hiltunen HA. Effect of rifampicin treatment on the kinetics of mexiletine. Eur J Clin Pharmacol 1982; 23: 261-6
66. 66. Santoni Y, Bruno R, Fornaris M, et al. Pharmacocinétique et biodisponibilité relative chez le sujet sain d'une nouvelle forme orale de mexilétine à libération continue. Therapie 1983; 38: 341-4
67. 67. Grech-Bélanger O, Barbeau G, Kishka P, et al. Pharmacokinetics of mexiletine in the elderly. J Clin Pharmacol 1989; 29: 311-5
68. 68. Paczkowski D, Sadowski Z, Filipek M, et al. Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. Pol J Pharmacol Pharm 1990; 42: 365-76
69. 69. Katagiri Y, Nagasako S, Hayashibara M, et al. Salivary excretion of mexiletine in normal healthy volunteers. J Pharm Pharmacol 1991; 43: 513-5
70. 70. Broly F, Vandamme N, Caron J, et al. Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine. Life Sci 1991; 48: PL-123-8
71. 71. Ueno K, Yamaguchi R, Tanaka K, et al. Lack of a kinetic interaction between fluconazole and mexiletine. Eur J Clin Pharmacol 1996; 50: 129-31
72. 72. Kusumoto M, Ueno K, Tanaka K, et al. Lack of pharmacokinetic interaction between mexiletine and omeprazole. Ann Pharmacother 1998; 32: 182-4
73. 73. Labbé L. Rôle du CYP1A2 dans la pharmacocinétique de la mexilétine chez l'human [thesis]. Quebec City (Quebec): Laval University, 1995
74. 74. El Allaf D, Henrard L, Crochelet L, et al. Pharmacokinetics of mexiletine in renal insufficiency. Br J Clin Pharmacol 1982; 14: 431-5
75. 75. El Allaf D, Carlier J, Dressé A. Effects of age on the pharmacokinetics of mexiletine. Int J Clin Pharmacol Res 1986; 6: 303-7
76. 76. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-6
77. 77. Steiner E, Bertilsson L, Sawe J, et al. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988; 44: 431-5
78. 78. Price Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17: 102-5
79. 79. Zanger UM, Vilbois F, Hardwick JP, et al. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27: 5447-54
80. 80. Dayer P, Kronbach T, Eichelbaum M, et al. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol 1987; 36: 4145-52
81. 81. Kagimoto M, Heim M, Kagimoto K, et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990; 265: 17209-14
82. 82. Broly F, Libersa C, Lhermitte M. Mexiletine metabolism in vitro by human liver. Drug Metab Dispos 1990; 18: 362-8
83. 83. Broly F, Libersa C, Lhermitte M, et al. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol 1990; 39: 1045-53
84. 84. Sesardic D, Boobis AR, Edwards RJ, et al. A form of cytochrome P450 in man, orthologous to fonn d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988; 26: 363-72
85. 85. Nakajima M, Kohayashi K, Shimada N, et al. Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol 1998; 46: 55-62
86. 86. Abolfathi Z, Pakdel H, Beaune P, et al. CYP1A2 is the major enzyme involved in the N-oxidation of mexiletine in man [abstract]. Clin Pharmacol Ther 1995; 57: 215
87. 87. Sesardic D, Boobis AR, Murray BP, et al. Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. Br J Clin Pharmacol 1990; 29: 651-63
88. 88. Turgeon J, Uprichard ACG, Bélanger PM, et al. Resolution and electrophysiological effects of mexiletine enantiomers. J Pharm Pharmacol 1991; 43: 630-5
89. 89. Hill RJ, Duff HJ, Sheldon RS. Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels. Mol Pharmacol 1988; 34: 659-63
90. 90. De Luca A, Natuzzi F, Lentini G, et al. Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 653-61
91. 91. Igwemezie L, Kerr CR, McErlane KM. The pharmacokinetics of the enantiomers of mexiletine in humans. Xenobiotica 1989; 19: 677-82
92. 92. McErlane KM, Igwemezie L, Kerr CR. Stereoselective serum protein binding of mexiletine enantiomers in man. Res Commun Chem Pathol Pharmacol 1987; 56: 141-4
93. 93. Abolfathi Z, Fiset C, Gilbert M, et al. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans. J Pharmacol Exp Ther 1993; 266: 1196-201
94. 94. Labbé L, Abolfathi Z, Robitaille NM, et al. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. Ther Drug Monit 1999; 21: 191-9
95. 95. Lanchote VL, Cesarino EJ, Santos VJ, et al. Enantioselectivity in the metabolism of mexiletine by conjugation in female patients with the arrhythmic form of chronic Chagas' heart disease. Chirality 1999; 11: 29-32
96. 96. Lanchote VL, Cesarino EJ, Santos VJ, et al. Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. Eur J Drug Metab Pharmacokinet 1998; 23: 259-66
97. 97. Lanchote VL, Bonato PS, Cesarino EJ, et al. HPLC determination of the enantiomeric metabolites of mexiletine in human plasma. Chirality 1997; 9: 722-6
98. 98. Vandamme N, Broly F, Libersa C, et al. Stereoselective hydroxylation of mexiletine in human liver microsomes: implication of P450IID6. A preliminary report. J Cardiovasc Pharmacol 1993; 21: 77-83
99. 99. Knoche B, Gehrcke B, Konig WA, et al. Determination of the enantiomeric composition of mexiletine and its four hydroxylated metabolites in urine by enantioselective capillary gas chromatography. Chirality 1996; 8: 30-4
100. 100. Ueno K, Kawaguchi Y, Tanaka K. Pharmacokinetics of mexiletine in middle-aged and elderly patients. Clin Pharmacokinet 1993; 12: 768-70
101. 101. Uenaka K, Koue T, Iwai T, et al. Population pharmacokinetic analysis of mexiletine in adult arrhythmic patients in Japanese population. Biol Pharm Bull 1998; 21: 844-6
102. 102. Fukagawa NF, Bandini LG, Young JB. Effect of age on body composition and resting metabolic rate. Am J Physiol 1990; 259: E233-8
103. 103. Nitsch J, Steinbeck G, Lüderitz B. Effect of kidney, liver or heart insufficiency on blood mexiletine levels. Internist 1982; 23: 291-3
104. 104. Nitsch J, Steinbeck G, Luderitz B. Increase of mexiletine plasma levels due to delayed hepatic metabolism in patients with chronic liver disease. Eur Heart J 1983; 4: 810-4
105. 105. Wang T, Wuellner D, Woosley RL, et al. Pharmacokinetics and nondialyzability of mexiletine in renal failure. Clin Pharmacol Ther 1985; 37: 649-53
106. 106. Herbinger W, Kramar R, Fridrik M, et al. Pharmakokinetische untersuchungen mit mexiletin bei patienten mit nierenin-suffizienz. Adv Clin Pharmacol 1978; 16: 17-27
107. 107. Baudinet G, Henrard L, Quinaux N, et al. Pharmacokinetics of mexiletine in renal insufficiency. Acta Cardiol 1980; 25: 55-65
108. 108. Evers J, Messer W, Aboudan F, et al. Mexiletine in terminal renal failure and various dialysis procedures. Klin Wochenschr 1989; 67: 995-8
109. 109. Jones TH, Reece PA, Fisher GC. Mexiletine removal by peritoneal dialysis. Eur J Clin Pharmacol 1983; 25: 839-40
110. 110. Guay DRP, Meatherall RC, Ferguson I, et al. Mexiletine clearance during peritoneal dialysis. Br J Clin Pharmacol 1985; 19: 857-8
111. 111. Pentikäinen PJ, Halinen MO, Helin MJ. Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction. J Cardiovasc Pharmacol 1984; 6: 1-6
112. 112. Pentikäinen PJ, Halinen MO, Helin MJ. Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. Eur J Clin Pharmacol 1983; 25: 773-7
113. 113. Pottage A, Campbell RWF, Achuff SC, et al. The absorption of oral mexiletine in coronary care patients. Eur J Clin Pharmacol 1978; 13: 393-9
114. 114. Lévy-Prades R, Philip F, Danays T, et al. Mexiletine in acute myocardial infarction. Simulation of a theoretical protocol and validation in six patients. Drug Res 1989; 39: 903-8
115. 115. Leahey Jr EB, Giardina EGV, Bigger Jr JT. Effect of ventricular failure on steady state kinetics of mexiletine [abstract]. Clin Res 1980; 28: 239A
116. 116. Vozeh S, Katz G, Steiner V, et al. Population pharmacokinetic parameters in patients treated with oral mexiletine. Eur J Clin Pharmacol 1982; 23: 445-51
117. 117. Ohashi K, Ebihara A, Hashimoto T, et al. Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. Drug Res 1984; 34: 503-7
118. 118. Nattel S, Heger JJ, Rinkenberger RL, et al. The pharmacokinetics of mexiletine in patients with refractory ventricular arrhythmias [abstract]. Clin Res 1979; 27: 445A
119. 119. Heger JJ, Nattel S, Rinkenberger RL, et al. Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. Am J Cardiol 1980; 45: 627-32
120. 120. Hutt V, Pabst G, Salama Z, et al. Untersuchungen zur pharmakokinetik und bioverfugbarkeit einer neuen mexiletin-zubereitung an gesunden freiwilligen. Drug Res 1995; 45: 254-7
121. 121. Bruno R, Santoni Y, Iliadis A, et al. Simultaneous modelling of mexiletine and hydroxy-methyl-mexiletine data after single-and multiple-dose administration of a sustained-release mexiletine formulation. Biopharm Drug Disp 1992; 13: 481-93
122. 122. Cereghino JJ, Wilder BJ, Kupferberg HJ, et al. A single-dose study of mexiletine (Kö 1173). Epilepsia 1975; 16: 665-72
123. 123. Cereghino JJ, Brock JT, Van Meter JC, et al. A multiple-dose study of mexiletine (Kö 1173). Epilepsia 1975; 16: 673-7
124. 124. Kiddie MA, Royds RB, Shaw TRD. Preliminary studies on the pharmacology of an antidysrhythmic, Kö 1173, in man. Proc Br Pharmacol Soc 1973; 47: 674-5P
125. 125. Paalman ACA, Roos JC, Siebelink J, et al. Development of a dosage scheme for simultaneous intravenous and oral administration of mexiletine. Postgrad Med J 1977; 53 Suppl. 1: 128-32
126. 126. Upward JW, Holt DW, Jackson G. A study to compare the efficacy, plasma concentration profile and tolerability of conventional mexiletine and slow-release mexiletine. Eur Heart J 1984; 5: 247-52
127. 127. Smyllie HC, Doar JWH, Head CD, et al. A trial of intravenous and oral mexiletine in acute myocardial infarction. Eur J Clin Pharmacol 1984; 26: 537-42
128. 128. Nimmo WS, Heading RC, Wilson J, et al. Inhibition of gastric emptying and drug absorption hy narcotic analgesics. Br J Clin Pharmacol 1975; 2: 509-13
129. 129. Joeres R, Klinker H, Heusler H, et al. Influence of mexiletine on caffeine elimination. Pharmacol Ther 1987; 33: 163-9
130. PA (P-450IA2), the phenacetin O-decthylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86: 7696-700
131. 131. Berthou F, Flinois JP, Ratanasavanh D, et al. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 1991; 19: 561-7
132. 132. Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39: 321-6
133. 133. Ueno K, Miyai K, Seki T, et al. Interaction between theophylline and mexiletine. Ann Pharmacother 1990; 24: 471-2
134. 134. Stanley R, Comer T, Taylor JL, et al. Mexiletine-theophylline interaction. Am J Med 1989; 86: 733-4
135. 135. Ueno K, Miyai K, Kato M, et al. Mechanism of interaction between theophylline and mexiletine. Ann Pharmacother 1991; 25: 727-30
136. 136. Loi CM, Wei X, Vestal RE. Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. Clin Pharmacol Ther 1991; 49: 571-80
137. 137. Stoysich AM, Mohiuddin SM, Destache CJ, et al. Influence of mexiletine on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 1991; 31: 354-7
138. 138. Katz A, Buskila D, Sukenik S. Oral mexiletine-theophylline interaction. Int J Cardiol 1987; 17: 227-8
139. 139. Kendall JD, Chrymko MM, Cooper BE. Theophylline-mexiletine interaction: a case report. Pharmacotherapy 1992; 12: 416-8
140. 140. Hurwitz A, Vacek JL, Botteron GW, et al. Mexiletine effects on theophylline disposition. Clin Pharmacol Ther 1991; 50: 299-307
141. 141. Inafuku M, Suzuki T, Ohtsu F, et al. The effect of mexiletine on theophylline pharmacokinetics in patients with bronchial asthma. J Cardiol 1992; 22: 227-33
142. 142. Kessler KM, Interian Jr A, Cox M, et al. Proarrhythmia related to a kinetic and dynamic interaction of mexiletine and theophylline. Am Heart J 1989; 117: 964-6
143. 143. Fuhr U, Strobl G, Manaut F, et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993; 43: 191-9
144. 144. Healy DP, Polk RE, Kanawati L, et al. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989; 33: 474-8
145. 145. Brockmeyer NH, Breithaupt H, Ferdinand W, et al. Kinetics of oral and intravenous mexiletine: lack of effect of cimetidine and ranitidine. Eur J Clin Pharmacol 1989; 36: 375-8
146. 146. Leahey Jr EB, Reiffel JA, Giardina EGV, et al. The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin. Ann Intern Med 1980; 92: 605-8
147. 147. Saris SD, Lowenthal DT, Affrime MB. Steady-state digoxin concentration during oral mexiletine administration. Curr Ther Res 1983; 34: 662-6
148. 148. Labbé L. Metabolisme de la mexiletine chaz l'humain: role of CYP1A2 et interaction ave la propafenome [thesis]. Quebec City (Quebec): Laval University, 1999